Revelation Biosciences, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting beneficial ownership of 4.99% of Revelation Biosciences, Inc. common stock.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 323,241 shares, representing 7.80% of the outstanding common stock of Revelation Biosciences, Inc.
NASDAQ
Sabby Management, Hal Mintz, and Sabby Volatility Warrant Master Fund have collectively reported a 9.6% beneficial ownership stake in Revelation Biosciences, Inc.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Revelation Biosciences, Inc., holding 250,755 shares of common stock.
NASDAQ
Sabby Management, LLC, Sabby Volatility Warrant Master Fund Ltd, and Hal Mintz have reported a passive beneficial ownership of 4.9% in Revelation Biosciences, Inc. common stock.